College of Pharmacy
In this section
HelixTalk Episode #115 - What Every Pharmacist Should Know to Conquer Staph Aureus Infections
Date posted: June 30, 2020, 6:00 am
In this episode, we discuss the historical significance of Staphylococcus aureus including its patterns of antimicrobial resistance and recommended treatments.
- Nearly all Staphylococcus produce B-lactamase, an enzyme that degrades penicillin, amoxicillin, and ampicillin. These drugs are almost never appropriate for Staphylococcus aureus infections.
- Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to nearly all B-lactam antibiotics (penicillins, cephalosporins, carbapenems, etc.) because a single gene mutation makes it very difficult for B-lactam antibiotics to bind to its penicillin binding protein.
- Vancomycin is the drug of choice for severe infections caused by MRSA. Daptomycin and linezolid are possible alternative options in certain patients.
- MRSA SSTI infections are usually purulent in nature (associated with abscesses and pus/drainage). For patients with mild-moderate SSTIs, doxycycline or Bactrim (SMP/TMP) are the preferred options; however, incision and drainage is curative in the vast majority of cases.
- Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol. 2008;8(6):747‐763. doi:10.1016/j.meegid.2008.07.007
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2015 May 1;60(9):1448. Dosage error in article text]. Clin Infect Dis. 2014;59(2):e10‐e52. doi:10.1093/cid/ciu444.